{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-025061","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2026-05-22T20:55:24+00:00","discovered_at":"2026-05-22T20:56:00.271011+00:00","generated_at":"2026-05-22T20:58:03.305562+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"confidence":"high","headline":"Nasdaq notifies Ensysce of delisting risk for equity shortfall","bullets":["Received Nasdaq notice on May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement as of March 31, 2026.","Must submit a plan by July 6, 2026 (45 days) to regain compliance; if accepted, extension up to 180 days from May 21.","Company plans to submit a timely plan and explore options, but no assurance Nasdaq will accept or extension granted.","Failure could lead to delisting; company may appeal to Nasdaq Hearings Panel if plan rejected."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025061","json":"https://secwatch.observer/filing/0001493152-26-025061.json","markdown":"https://secwatch.observer/filing/0001493152-26-025061.md","text":"https://secwatch.observer/filing/0001493152-26-025061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T20:58:03.305562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e91685b29e13c8ef1e7ef543f0e47eb6853323c","claim":"Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"On May 21, 2026, Ensysce Biosciences Inc. (the “ Company ”) received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that due to the Company’s non-compliance with the $2.5 million stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) as of March 31, 2026, the Company is subject to delisting","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm","confidence":1.0},{"claim_id":"27087ce2350d9925d45f509f7b4401f26ea73cd9","claim":"Ensysce Biosciences, Inc. received a nasdaq other notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"If the plan is accepted, the Company may be granted an extension of up to 180 days from May 21, 2026, to regain compliance.","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm","confidence":1.0},{"claim_id":"5b8e9c59912ead1eb2b2aa24de4487549bcd80be","claim":"Ensysce Biosciences, Inc. received a nasdaq hearing update notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"If the plan is not accepted, the Company may appeal to the Nasdaq Hearings Panel (the “Panel”).","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm","confidence":1.0},{"claim_id":"7c00c28a878d949f315bb80553f1443ac1392b28","claim":"Ensysce Biosciences, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"unless it submits a plan within 45 days (by July 6, 2026) to regain compliance.","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm","confidence":1.0}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}